The Feasibility and Applicability of Pediatric Inpatient Beta Lactam De-Labeling: From Bedside Challenge to Long-Term Follow Up.

IF 2.9 Q2 INFECTIOUS DISEASES
Infection and Chemotherapy Pub Date : 2026-03-01 Epub Date: 2025-11-13 DOI:10.3947/ic.2025.0077
Michal Paret, Rinat Komargodski, Bella London, Hadas Paz, Naama Epstein Rigbi
{"title":"The Feasibility and Applicability of Pediatric Inpatient Beta Lactam De-Labeling: From Bedside Challenge to Long-Term Follow Up.","authors":"Michal Paret, Rinat Komargodski, Bella London, Hadas Paz, Naama Epstein Rigbi","doi":"10.3947/ic.2025.0077","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Beta-lactam allergy (BLA) labels are common in pediatric patients but are often inaccurate, leading to unnecessary use of second-line antibiotics. While direct oral challenge tests (OCTs) are effective for de-labeling, their implementation in inpatient pediatric settings remains underexplored. This study aimed to evaluate the feasibility and barriers of an inpatient pediatric BLA de-labeling program, from bedside OCT to long-term follow-up and integration into electronic medical records (EMRs).</p><p><strong>Materials and methods: </strong>We conducted a prospective interventional study in the pediatric ward between 2019 and 2024. Hospitalized children with a documented BLA were screened and eligible patients underwent a 2-step graded OCT. In-house pediatricians completed surveys to assess beliefs and barriers regarding inpatient OCT implementation. Long term follow-up included caregiver surveys and review of hospital and Health Maintenance Organization (HMO) EMRs to evaluate de-labeling documentation and subsequent beta-lactam use.</p><p><strong>Results: </strong>Of 192 eligible BLA-labeled patients, 32 (16.6%) were recruited, 93.8% carrying an amoxicillin allergy label and the vast majority without other drug allergy labels. All patients had a history of a mild reaction, 100% presented with a benign rash. 30/32 (93.4%) had a negative OCT. Pediatricians faced challenges such as workload pressures, staff shortages and overestimation of severe reaction risks, all serving as barriers for patient recruitment. At follow-up (median 37 months), 35.7% of caregivers reported de-labeling, while EMRs documented higher rates (HMO: 80%; hospital: 70%). Despite successful OCTs, discrepancies between caregiver understanding, physician attitudes, and EMR documentation persisted.</p><p><strong>Conclusion: </strong>While direct OCTs are proved to be effective in de-labeling BLA, significant challenges persist in implementing inpatient de-labeling and ensuring their long-term success. These include low recruitment rates, pediatricians' misconceptions and incomplete integration into EMRs. Addressing these barriers requires targeted education, improved communication, and streamlined processes to improve de-labeling outcomes and support antibiotic stewardship.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"29-38"},"PeriodicalIF":2.9000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13053898/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2025.0077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Beta-lactam allergy (BLA) labels are common in pediatric patients but are often inaccurate, leading to unnecessary use of second-line antibiotics. While direct oral challenge tests (OCTs) are effective for de-labeling, their implementation in inpatient pediatric settings remains underexplored. This study aimed to evaluate the feasibility and barriers of an inpatient pediatric BLA de-labeling program, from bedside OCT to long-term follow-up and integration into electronic medical records (EMRs).

Materials and methods: We conducted a prospective interventional study in the pediatric ward between 2019 and 2024. Hospitalized children with a documented BLA were screened and eligible patients underwent a 2-step graded OCT. In-house pediatricians completed surveys to assess beliefs and barriers regarding inpatient OCT implementation. Long term follow-up included caregiver surveys and review of hospital and Health Maintenance Organization (HMO) EMRs to evaluate de-labeling documentation and subsequent beta-lactam use.

Results: Of 192 eligible BLA-labeled patients, 32 (16.6%) were recruited, 93.8% carrying an amoxicillin allergy label and the vast majority without other drug allergy labels. All patients had a history of a mild reaction, 100% presented with a benign rash. 30/32 (93.4%) had a negative OCT. Pediatricians faced challenges such as workload pressures, staff shortages and overestimation of severe reaction risks, all serving as barriers for patient recruitment. At follow-up (median 37 months), 35.7% of caregivers reported de-labeling, while EMRs documented higher rates (HMO: 80%; hospital: 70%). Despite successful OCTs, discrepancies between caregiver understanding, physician attitudes, and EMR documentation persisted.

Conclusion: While direct OCTs are proved to be effective in de-labeling BLA, significant challenges persist in implementing inpatient de-labeling and ensuring their long-term success. These include low recruitment rates, pediatricians' misconceptions and incomplete integration into EMRs. Addressing these barriers requires targeted education, improved communication, and streamlined processes to improve de-labeling outcomes and support antibiotic stewardship.

儿科住院患者β -内酰胺去标签化的可行性和适用性:从床边挑战到长期随访。
背景:β -内酰胺过敏(BLA)标签在儿科患者中很常见,但往往不准确,导致不必要地使用二线抗生素。虽然直接口腔激发试验(OCTs)对去标签有效,但其在儿科住院环境中的实施仍未得到充分探索。本研究旨在评估住院儿童BLA去标签项目的可行性和障碍,从床边OCT到长期随访,并整合到电子病历(EMRs)中。材料与方法:我们于2019 - 2024年在儿科病房进行了前瞻性介入研究。对有BLA记录的住院儿童进行筛查,并对符合条件的患者进行两步OCT分级。医院儿科医生完成调查,以评估住院患者实施OCT的信念和障碍。长期随访包括护理人员调查和对医院和健康维护组织(HMO)电子病历的审查,以评估去标签文件和随后的β -内酰胺使用情况。结果:192例符合bla标签的患者中,32例(16.6%)入选,93.8%携带阿莫西林过敏标签,绝大多数没有其他药物过敏标签。所有患者均有轻度反应史,100%表现为良性皮疹。30/32(93.4%)患儿的oct评分为负,儿科医生面临着工作量压力、人员短缺和对严重反应风险的高估等挑战,这些都是招募患者的障碍。在随访中(中位37个月),35.7%的护理人员报告去标签,而电子病历记录的比例更高(HMO: 80%;医院:70%)。尽管oct治疗成功,但护理人员的理解、医生的态度和电子病历记录之间的差异仍然存在。结论:虽然直接oct被证明对BLA去标签有效,但在实施住院患者去标签并确保其长期成功方面仍然存在重大挑战。其中包括低招聘率,儿科医生的误解和不完全融入电子病历。解决这些障碍需要有针对性的教育、改善沟通和简化流程,以改善去标签结果并支持抗生素管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Infection and Chemotherapy
Infection and Chemotherapy INFECTIOUS DISEASES-
CiteScore
6.60
自引率
11.90%
发文量
71
审稿时长
22 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书